BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38317839)

  • 1. DLX1 acts as a novel prognostic biomarker involved in immune cell infiltration and tumor progression in lung adenocarcinoma.
    Du Y; Li H; Wang Y; He Y; Li G
    PeerJ; 2024; 12():e16823. PubMed ID: 38317839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRPL12 Acts as A Novel Prognostic Biomarker Involved in Immune Cell Infiltration and Tumor Progression of Lung Adenocarcinoma.
    Hu Y; Liu Y; Ma C; Ai K
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
    Zhang X; Wu Z; Ma K
    BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma.
    Chen R; Wang Z; Lu T; Liu Y; Ji Y; Yu Y; Tou F; Guo S
    Thorac Cancer; 2023 Apr; 14(10):893-912. PubMed ID: 36825773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
    Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
    PeerJ; 2023; 11():e16166. PubMed ID: 37790630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target.
    Chen M; Zhang S; Wang F; He J; Jiang W; Zhang L
    J Transl Med; 2024 Feb; 22(1):209. PubMed ID: 38414025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
    Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
    Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIP serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.
    Jing Y; Mao Z; Zhu J; Ma X; Liu H; Chen F
    Int Immunopharmacol; 2023 Sep; 122():110605. PubMed ID: 37451021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
    Fan K; Zhang BH; Han D; Sun YC
    BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
    Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
    Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma.
    Yu Y; Wang Z; Zheng Q; Li J
    Gene; 2021 Jul; 790():145689. PubMed ID: 33964375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of HOXB3 predicts poor prognosis and correlates with tumor immunity in lung adenocarcinoma.
    Yan M; Yin X; Zhang L; Cui Y; Ma X
    Mol Biol Rep; 2022 Apr; 49(4):2607-2618. PubMed ID: 35028857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of BCCIP predicts an unfavorable prognosis and promotes the proliferation and migration of lung adenocarcinoma.
    Shi J; Lv X; Li W; Ming Z; Zeng L; Yuan J; Chen Y; Liu B; Yang S
    Thorac Cancer; 2021 Sep; 12(17):2324-2338. PubMed ID: 34297484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma.
    Wei S; Xing J; Lu K; Wang K; Yu W
    Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
    Liu W; Du Q; Mei T; Wang J; Huang D; Qin T
    BMC Cancer; 2024 Jan; 24(1):94. PubMed ID: 38233752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.